Study Shows COVID-19 Infection Correlates with Autoimmune Markers
A new study demonstrates how severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) infection could be associated with an autoimmune response and development of autoantibodies.
Transition from Clinic- to Home-Based IVIG/SCIG Is Successful to Decrease Exposure to COVID-19
Transition of clinic-based to home-based intravenous immune globulin (IVIG)/subcutaneous IG (SCIG) infusion can be successfully done to decrease potential exposure during a pandemic in a high-risk immunosuppressed population.
IVIG Plus Glucocorticoids Effective for Treating COVID-19 Pediatric Syndrome
A large multicenter clinical trial has found intravenous immune globulin (IVIG) plus glucocorticoids may be better than IVIG alone for treating multisystem inflammatory syndrome in children (MIS-C) caused by COVID-19.
Studies Reveal Antibody Responses of Pregnant Women Infected with SARS-CoV-2
Two recent studies effectively determined the antibody responses of pregnant women infected with SARS-CoV-2 and the effect of the fetal sex on those responses, as well as the direct clinical implications for COVID-19 infection and future maternal-fetal vaccination strategies.
Gene Therapy for Hemoglobinopathies
New clinical studies show gene therapy may offer a cure for these chronic and expensive diseases in five to 10 years.
High Oncotic Pressure Cardiopulmonary Bypass Priming with Human Albumin Improves Outcomes in Pediatric Open-Heart Surgery
Specialists at India’s Sir Ganga Ram Hospital conducted a double-blinded, randomized controlled study to examine the impact of high oncotic pressure priming by the addition of 20 percent human albumin prior to the initiation of CPB
First-Line Intravenous Immune Globulin Monotherapy Evaluated in Idiopathic Inflammatory Myopathy
The investigators concluded first-line IVIG monotherapy led to clinically relevant improvement in nearly one-half of IIM patients, the majority of whom experienced a rapid clinical response.
Decentralized Clinical Trials: Coming Virtually to a Research Facility Near You
Virtual clinical trials may increasingly replace in-person trials due to their advantages in helping to bring drugs to market.
Subcutaneous Immune Globulin May Be a Treatment Option in Stiff Person Syndrome Patients Intolerant to Intravenous Immune Globulin
SCIG may be a reasonable and safe alternative for SPS patients who do not tolerate IVIG, with the caveat that allergic and injection site reactions can be a limiting factor for some patients.
Low Rate of Inhibitor Development in Previously Untreated Hemophilia A Patients Managed with Simoctocog Alfa (Nuwiq)
The investigators concluded PUPs treated with simoctocog alfa had a lower high-titer inhibitor rate than PUPs initially treated with hamster-cell-derived recombinant FVIII products.